---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Long-term morbidity"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Long-term morbidity. Topics: Severe late toxicity after concurrent chemoradiotherapy; Swallowing, speech, and voice impairment in survivors; Chronic dysphagia and aspiration after combined modality therapy; Lymphedema and other long-term effects of surgery and radiotherapy; 2 further topics. 6 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Severe late toxicity after concurrent chemoradiotherapy

> “Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube ≥ 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years.”
> “A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity.”

Source: [Machtay et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911537/)

<a id="topic-2.2.1.7-2"></a>

### Swallowing, speech, and voice impairment in survivors

> “Swallowing and speech impairments occur in ~50% of HNSCC survivors following radiotherapy treatment and are often present long-term”
> “For example, a majority (68%) of HNSCC survivors reported voice problems even 10 years after radiotherapy”
> “Furthermore, the two-year prevalence of dysphagia is 45% among HNSCC survivors (all therapies) and is 4–8 times more likely to occur in these individuals than in those who never had cancer”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-3"></a>

### Chronic dysphagia and aspiration after combined modality therapy

> “Combined modality therapy is associated with substantial acute and late toxicities, including chronic dysphagia with a risk of aspiration pneumonia, and possibly increased non-cancer mortality”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-4"></a>

### Lymphedema and other long-term effects of surgery and radiotherapy

> “However, if lymph nodes are removed, the flow of lymph in the area where they were removed may be slower and lymph could collect in the tissues (a condition called lymphedema), causing additional swelling that may last for a long time.”
> “Although side effects will improve slowly over time in many patients, others will experience long-term side effects of surgery or radiation therapy, including difficulty swallowing, speech impairment, and skin changes”

Source: [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)

<a id="topic-2.2.1.7-5"></a>

### Second primary tumors after HPV-negative disease

> “As such, patients with a first HPV-negative HNSCC are at high risk for a SPT of the upper aerodigestive tract, including in the head and neck, oesophagus or lung”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.7-6"></a>

### Suicide among survivors

> “In addition to deaths directly caused by HNSCC, survivors of this cancer have the second highest rate of suicide (63.4 cases per 100,000 individuals) after those with pancreatic cancer (86.4 cases per 100,000 individuals), compared with survivors of other cancers (23.6 cases per 100,000 individuals).”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
